Our group has previously observed that the vast majority of patients with TN and HER2+ breast cancer are seen first by a surgeon following diagnosis, highlighting the surgeon–medical oncologist referral pathway as an important target for further study [2]. This evidence concerns the gene ERBB2 and breast cancer.